abstract |
The present invention relates to drug field, specially oncology.The invention discloses the delivering in vivo system of the optimization with endosome lytic agent for nucleic conjugate.In particular it relates to the delivering in vivo system of optimization nucleic acid, with endosome lytic agent for having therapeutical uses combined for the molecule with promotion endocytosis, in particular for treating cancer. |